MDR1 causes resistance to the antitumour drug miltefosine

Miltefosine (hexadecylphosphocholine) is used for topical treatment of breast cancers. It has been shown previously that a high percentage of breast carcinomas express MDR1 or MRP. We investigated the sensitivity of MDR1 -expressing cells to treatment with miltefosine. We show that cells overexpress...

Descripción completa

Detalles Bibliográficos
Autores principales: Rybczynska, M, Liu, R, Lu, P, Sharom, F J, Steinfels, E, Pietro, A Di, Spitaler, M, Grunicke, H, Hofmann, J
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2001
Materias:
Regular Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363649/
https://www.ncbi.nlm.nih.gov/pubmed/11355955
http://dx.doi.org/10.1054/bjoc.2001.1776

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363649/
https://www.ncbi.nlm.nih.gov/pubmed/11355955
http://dx.doi.org/10.1054/bjoc.2001.1776

Ejemplares similares